| RYCYX | RYVLX | RYCYX / RYVLX | |
| Total Expense Ratio | 2.53 | 1.74 | 145% |
| Annual Report Gross Expense Ratio | 2.62 | 1.87 | 140% |
| Fund Existence | 22 years | 22 years | - |
| Gain YTD | 15.206 | 18.430 | 83% |
| Front Load | N/A | 5% | - |
| Min. Initial Investment | 2500 | 2500 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 43.2M | 1.59B | 3% |
| Annual Yield % from dividends | 0.66 | 0.00 | - |
| Returns for 1 year | 32.22 | 26.31 | 122% |
| Returns for 3 years | 71.95 | 112.92 | 64% |
| Returns for 5 years | 53.34 | 81.53 | 65% |
| Returns for 10 years | 317.78 | 882.86 | 36% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BKMIX | 10.64 | 0.05 | +0.51% |
| BlackRock Multi-Asset Income Portfolio K | |||
| THPBX | 25.66 | 0.10 | +0.39% |
| BNY Mellon Balanced Opportunity J | |||
| DRRCX | 16.92 | 0.02 | +0.12% |
| BNY Mellon Global Real Return - C | |||
| FMPOX | 37.87 | -0.11 | -0.29% |
| Fidelity Advisor Mid Cap Value I | |||
| LYFCX | 17.38 | -0.49 | -2.74% |
| AlphaCentric Life Sciences & Hlthcare C | |||